Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 9:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 153 matching trials from the live ClinicalTrials.gov search.
Conditions
Late Onset Alzheimer Disease
Interventions
BAY 94-9172 (Florbetaben)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
65 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more
Conditions
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease 4, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 7, Alzheimer Disease 8, Alzheimer Disease 9, Late-Onset, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 17, Alzheimer Disease 18, Alzheimer Disease 19, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease Focal
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Conditions
Empaglifozin, Physiological Effects of Drugs, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors
Interventions
empagliflozin (Jardiance) 25 mg
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Alzheimer Disease, Dementia, Medication Adherence, Type 2 Diabetes Mellitus (T2DM)
Interventions
HiDO-ALZ
Device
Lead sponsor
HiDO Technologies
Industry
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Alzheimer's Disease, Dementia
Interventions
Drug: EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
55 Years to 85 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
42
States / cities
Tucson, Arizona • Little Rock, Arkansas • Culver City, California + 39 more
Completed Not applicable Interventional Accepts healthy volunteers

SAGE LEAF 2: An Online Program to Reduce Dementia Caregiver Burden

NCT06708182
Conditions
Caregiving Stress, Caregiver Burden
Interventions
SAGE LEAF Positive Emotion Skills Course
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Caregiver Burden, Alzheimer Disease
Interventions
Brain CareNotes, Dementia Guide Expert
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Bloomington, Indiana
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Stamford, Connecticut + 9 more
Recruiting No phase listed Observational Accepts healthy volunteers

Late Onset Alzheimer's Disease

NCT05010603
Conditions
Alzheimer Disease
Interventions
Blood Draw, Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test
Genetic · Other
Lead sponsor
Columbia University
Other
Eligibility
55 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Miami, Florida • Aurora, Illinois + 9 more
Conditions
Alzheimer Disease, Diabetes Mellitus, Type 2
Interventions
Tailored Lighting Intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
New Brunswick, New Jersey • Albany, New York • New York, New York
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
9
States / cities
Irvine, California • Delray Beach, Florida • Fort Myers, Florida + 6 more
Conditions
AL Amyloidosis
Interventions
Ixazomib, Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
New York, New York
Conditions
Alzheimer Disease, Parkinson Disease, Inflammation
Interventions
GE180 PET Scan
Drug
Lead sponsor
Aaron Ritter, MD
Other
Eligibility
55 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Mild Cognitive Impairment
Interventions
Circadian-Effective Light, Rhythmic Light, Placebo Light, Placebo Rhythmic Light
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Menands, New York • New York, New York
Conditions
Alzheimer's Disease
Interventions
KarXT, KarX-EC, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
60 Years to 85 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
32
States / cities
Fullerton, California • Irvine, California • Los Angeles, California + 29 more
Conditions
Alzheimer's Disease, Dementia
Interventions
Drug: EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
55 Years to 85 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
44
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 41 more
Completed Not applicable Interventional Results available

Optimizing Care for Patients With Dementia

NCT03442322
Conditions
Alzheimer Disease
Interventions
transdisciplinary approach, multidisciplinary approach
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Alzheimer Disease
Interventions
PF-04494700 - Low Dose Arm, PF-04494700 - High Dose Arm, Placebo Comparator
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
12
States / cities
Sun City, Arizona • Fresno, California • San Diego, California + 9 more
Conditions
Alzheimer's Disease
Interventions
Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
93
States / cities
Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
grape seed polyphenolic extract, resveratrol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Alzheimer's Disease
Interventions
TC-5619, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
10
States / cities
Long Beach, California • San Francisco, California • Hallandale, Florida + 7 more
Conditions
Alzheimer Disease
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
185
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 146 more
Conditions
Alzheimer's Disease
Interventions
Curcumin C3 Complex
Dietary Supplement
Lead sponsor
John Douglas French Foundation
Other
Eligibility
50 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Westwood, Los Angeles, California